OS Therapies’ (OSTX) “Buy” Rating Reaffirmed at D. Boral Capital

OS Therapies (NYSEAMERICAN:OSTX)‘s stock had its “buy” rating reissued by stock analysts at D. Boral Capital in a report released on Wednesday,Benzinga reports. They currently have a $20.00 price target on the stock.

OS Therapies Price Performance

OS Therapies stock opened at $1.23 on Wednesday. The stock has a market cap of $48.62 million, a price-to-earnings ratio of -1.24 and a beta of -2.98. OS Therapies has a 1 year low of $1.12 and a 1 year high of $2.57. The firm has a 50-day moving average of $1.38 and a two-hundred day moving average of $1.63.

OS Therapies (NYSEAMERICAN:OSTX) last released its quarterly earnings data on Tuesday, March 31st. The company reported ($0.41) earnings per share (EPS) for the quarter. Research analysts expect that OS Therapies will post -0.64 earnings per share for the current year.

Institutional Investors Weigh In On OS Therapies

Hedge funds have recently modified their holdings of the business. Geode Capital Management LLC lifted its position in shares of OS Therapies by 31.1% in the 4th quarter. Geode Capital Management LLC now owns 246,038 shares of the company’s stock worth $344,000 after purchasing an additional 58,350 shares during the period. Millennium Management LLC purchased a new stake in shares of OS Therapies in the 3rd quarter worth approximately $183,000. Two Sigma Investments LP purchased a new stake in shares of OS Therapies in the 3rd quarter worth approximately $169,000. Virtu Financial LLC lifted its position in shares of OS Therapies by 252.0% in the 3rd quarter. Virtu Financial LLC now owns 75,801 shares of the company’s stock worth $149,000 after purchasing an additional 54,269 shares during the period. Finally, State Street Corp lifted its position in shares of OS Therapies by 16.3% in the 4th quarter. State Street Corp now owns 58,500 shares of the company’s stock worth $82,000 after purchasing an additional 8,200 shares during the period.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.